Definitive Contract HHSO100200700032C
Award Date
1/3/07
Potential Completion Date
4/30/14
Potential Value
$205M
Awardee
Biocryst Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Bluff Park, AL 35244, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Biocryst Pharmaceuticals Inc., a biotechnology company specializing in small molecule drugs for rare diseases. The $47,755,722.77 cost-plus-fixed-fee contract is for the development of medical countermeasures for biodefense and emerging infectious diseases. The contract has a base period from September 16, 2013, to September 15, 2017, with two option periods...
This is a firm fixed-price purchase order awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to Biocryst Pharmaceuticals Inc., a small business. The $134,064 contract is for the Peramivir Stability Extension Program, which involves the delivery of the influenza treatment drug peramivir. Biocryst Pharmaceuticals is a biotechnology company that specializes in developing small molecule drugs for rare diseases. The company primarily provides...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a Definitive Contract to Biocryst Pharmaceuticals Inc., a for-profit biotechnology company, for the delivery of PERAMIVIR, RAPIVAB flu treatment. The contract has a Firm Fixed Price pricing type, a potential value of $34,660,000.00, and a period of performance through August 31, 2023. This contract is not associated with a set-aside designation. Biocryst Pharmaceuticals is a...
This federal contract award is for the delivery of the pharmaceutical product ORLADEYO (berotralstat) to the Department of Veterans Affairs (VA) through the Veterans Integrated Service Network 20 (VISN 20). The prime contractor is Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. The contract is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs, which has a ceiling...
This federal contract award, valued at $7,521,000.00, was issued by the Centers for Disease Control and Prevention (CDC) to Protein Sciences Corp, a for-profit manufacturer, to conduct research, development, manufacturing, and testing of vaccine candidates, antigens, proteins, seed lots, and assays to support medical countermeasure preparedness against influenza strains and COVID-19. The award is part of the Department of Health and Human Services' (HHS) Office of the Assistant Secretary for...
This federal contract award is for the delivery of BEROTRALSTAT HCL 150MG CAP (trade name ORLADEYO 150MG CAP) to the U.S. Department of Veterans Affairs (VA). The $379,348.93 contract was awarded to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. This is a Firm Fixed Price delivery order placed under Biocryst's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has an...
This federal contract award was made by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Seqirus Inc., a division of the global biotechnology company CSL Seqirus. The $18,890,210.47 fixed-price delivery order is for the acquisition of medical countermeasures for pandemic influenza preparedness and response. The contract is a task order under a larger $13.4 billion Indefinite Delivery Contract (IDC) awarded by HHS...
The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $63,239,785.00 definitive contract to Arcturus Therapeutics, Inc. for the procurement of a pandemic influenza vaccine (PandFlu) and a quadrivalent seasonal influenza vaccine (QsFlu). This contract is not a set-aside and supports the Arcturus self-amplifying mRNA-based vaccine platform for rapid pandemic influenza response, a key priority under ASPR's Biomedical...
This federal contract award to Protein Sciences Corp, a for-profit manufacturer, was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS). The $14,675 firm-fixed-price purchase order is for the provision of tested influenza virus proteins. The contract does not have a set-aside designation. Protein Sciences has received multiple previous federal contract awards from the HHS Office of the Assistant Secretary...
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded a $664,774 firm-fixed-price contract to US Biologic, Inc. for the development of a rapid-response oral influenza vaccine. This contract was awarded under a Broad Agency Announcement (BAA) that sought research and development of innovative medical countermeasures. The contract has a completion date of February 29, 2024 and was not set aside for any specific business type. The...